Literature DB >> 7844386

Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C.

C Y Chan1, S D Lee, S J Hwang, R H Lu, C L Lu, K J Lo.   

Abstract

To determine the value of a quantitative branched DNA (bDNA) assay for detection of hepatitis C virus (HCV) RNA, 309 serum specimens were collected from 100 patients with acute or chronic hepatitis C for detection of HCV RNA by bDNA assay and reverse transcription-polymerase chain reaction (RT-PCR) assay. There were 256 samples positive by RT-PCR; 199 (78%) were also positive by bDNA assay. All but 1 of the remaining 53 samples negative by RT-PCR were also negative by bDNA assay. Combination of the two methods clearly demonstrated changes in HCV RNA titers during and after interferon (IFN) treatment. The most common genotype of HCV infection was Okamoto type II (Simmonds type 1b, 60.0%), followed by type III (type 2a, 16.5%) and type IV (type 2b, 8.2%); mixed or underdetermined types were noted in 15.3%. Patients with chronic type II HCV infection tended to have higher HCV RNA titers. These findings suggest that the bDNA assay is a reliable test for HCV RNA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844386     DOI: 10.1093/infdis/171.2.443

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method.

Authors:  A Hawkins; F Davidson; P Simmonds
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

2.  Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.

Authors:  J Mellor; A Hawkins; P Simmonds
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

3.  Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus.

Authors:  J Hayashi; Y Kawakami; A Nabeshima; Y Kishihara; N Furusyo; Y Sawayama; N Kinukawa; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

4.  Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay.

Authors:  R H Lu; S J Hwang; C Y Chan; F Y Chang; S D Lee
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

5.  Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.

Authors:  J Detmer; R Lagier; J Flynn; C Zayati; J Kolberg; M Collins; M Urdea; R Sánchez-Pescador
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

6.  Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China.

Authors:  Jin-Song Peng; Xu Wang; Man-Qing Liu; Dun-Jin Zhou; Jie Gong; Han-Ming Xu; Jian-Ping Chen; Hong-Hao Zhu; Wang Zhou; Wen-Zhe Ho
Journal:  Virus Res       Date:  2008-03-18       Impact factor: 3.303

7.  Low Prevalence of Hepatitis C Virus Genotype -1b in Chronic Liver Disease Patients in India.

Authors:  V Thakur; R C Guptan; M Geeret; B C Das; S K Sarin
Journal:  EJIFCC       Date:  2003-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.